Reaction
Nephrocalcinosis reporting signals
As of the last recalculation, Nephrocalcinosis appears in 1,168 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is ASFOTASE ALFA (PRR 92.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Asfotase Alfa | 50 | 92.9 | 93.3 |
| Calcitriol Capsules 0.25 Mcg | 79 | 75.3 | 75.6 |
| Calcitriol Capsules 0.5 Mcg | 79 | 75.3 | 75.6 |
| Calcitriol | 79 | 74.4 | 74.7 |
| Antacid | 68 | 27.0 | 27.1 |
| Atazanavir | 19 | 23.9 | 24.0 |
| Calcium Carbonate | 73 | 20.6 | 20.6 |
| Abacavir Sulfate | 10 | 18.4 | 18.5 |
| Anti-Thymocyte Globulin (Rabbit) | 7 | 15.6 | 15.6 |
| Gentamicin | 11 | 15.1 | 15.1 |
| Ritonavir | 23 | 14.3 | 14.3 |
| Raltegravir | 13 | 14.2 | 14.2 |
| Valproic Acid | 22 | 12.7 | 12.7 |
| Canakinumab | 7 | 11.6 | 11.6 |
| Ritonavir 100 Mg | 9 | 10.8 | 10.8 |
| Tenofovir Disoproxil Fumarate | 13 | 7.1 | 7.1 |
| Cinacalcet Hydrochloride | 18 | 7.0 | 7.0 |
| Vigabatrin | 5 | 6.1 | 6.1 |
| Palivizumab | 3 | 3.5 | 3.5 |